EGFR
Clinical trials for EGFR explained in plain language.
Never miss a new study
Get alerted when new EGFR trials appear
Sign up with your email to follow new studies for EGFR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody EPI-326 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study is testing a new drug called EPI-326 in people with advanced lung cancer (with EGFR mutations) or head & neck cancer. EPI-326 is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the right dose, a…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Jun 23, 2026 22:19 UTC
-
Can a salt substitute save your kidneys after tumor surgery?
Disease control Recruiting nowThis study tests whether using a low-sodium, potassium-enriched salt substitute instead of regular salt can help protect kidney function in people who have had surgery for a kidney tumor. Two hundred adults who had a partial or full kidney removal will either use the salt substit…
Matched conditions: EGFR
Phase: NA • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New combo aims to shield bone marrow in Tough-to-Treat lung cancer
Disease control Recruiting nowThis study tests whether giving a bone marrow-protecting drug (trilaciclib) before chemotherapy (sacituzumab tirumotecan) can reduce serious side effects like low blood cell counts in people with advanced EGFR-mutated lung cancer that has stopped responding to standard treatments…
Matched conditions: EGFR
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New pill shows promise against tough lung cancer mutations
Disease control Recruiting nowThis study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…
Matched conditions: EGFR
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New cancer drug VIR-5525 enters first human trials for EGFR-Positive tumors
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New hope for lung cancer patients whose drugs have failed
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer that has stopped responding to a type of targeted therapy called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug called befotertinib, can help con…
Matched conditions: EGFR
Phase: PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC
-
New study tracks amivantamab combo in Real-World lung cancer patients
Knowledge-focused Recruiting nowThis observational study is following 100 adults with metastatic non-small cell lung cancer who have certain EGFR mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers want to see how long the treatment keeps the can…
Matched conditions: EGFR
Sponsor: GFPC Investigation • Aim: Knowledge-focused
Last updated Jun 23, 2026 12:00 UTC